Preferred Label : Pola-BR Regimen;
NCIt synonyms : Bendamustine/Polatuzumab Vedotin/Rituximab; Bendamustine/Polatuzumab Vedotin/Rituximab Regimen; Polatuzumab Vedotin-Bendamustine/Rituximab Regimen; Bendamustine-Polatuzumab Vedotin-Rituximab; Bendamustine-Polatuzumab Vedotin-Rituximab Regimen; Bendamustine/Polivy/Rituxan Regimen; Polatuzumab Vedotin-BR Regimen; Polatuzumab Vedotin Plus Bendamustine/Rituximab; Polatuzumab Vedotin-piiq Plus Bendamustine/Rituximab;
NCIt related terms : Bendamustine and Rituximab (BR) and Polatuzumab vedotin; Bendamustine and Rituximab-abbs (BR) and Polatuzumab vedotin; Bendamustine and Rituximab-rixa (BR) and Polatuzumab vedotin; Bendamustine and Rituximab-pvvr (BR) and Polatuzumab vedotin; Bendamustine and Rituximab-rite (BR) and Polatuzumab vedotin; Bendamustine and Rituximab-blit (BR) and Polatuzumab vedotin; Bendamustine and Rituximab-rixi (BR) and Polatuzumab vedotin; Bendamustine and Rituximab-arrx (BR) and Polatuzumab vedotin;
NCIt definition : A regimen consisting of polatuzumab vedotin, bendamustine and rituximab that may be
used in the treatment of diffuse large B-cell lymphoma (DLBCL).;
NCI Metathesaurus CUI : CL1794043;
Codes from synonyms : 36282; 128116; 127802; 128273; 128430; 127959; 128587; 128744;
Origin ID : C188903;
UMLS CUI : C5708111;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
